Fraunhofer IZI will give the company $425,000 over two years.
Cytori Therapeutics and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) are collaborating to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The Fraunhofer Society will commit $425,000 over two years to support the company’s already planned R&D activities.
The goal is to advance adipose-derived stem and regenerative cells into clinical trials for ischemic stroke. The underlying damage in ischemic stroke is brought about by a loss of blood flow to the brain. Because adipose-derived stem and regenerative cells have been shown to improve tissue outcome during injury resulting from a reduction in blood flow, it is believed that these cells could represent a novel approach for reducing stroke-induced damage, the organizations explain.
“In combining the competencies of both partners in regenerative medicine, we will have the promising opportunity to develop a novel therapeutic strategy that might have the potential to beneficially influence functional recovery following ischemic stroke,” comments Johannes Boltze, head of the neurorepair research group at Fraunhofer IZI.
“For this, a step-wise experimental approach including small and large animal studies adhering to the strict STAIR-criteria for stroke therapy development will be utilized.” Cytori will contribute its knowledge in adipose-derived stem and regenerative cell biology as it relates to cardiovascular conditions. At the end of the two-year term, Cytori will have the opportunity to advance the work into clinical trials and through to commercialization.
Navigating Stem Cell Fact and Fiction
Cytori Closes 2nd Half of $12 Million Equity Agreement with Green Hospital Supply
Three Month Results Reported from Stem & Regenerative Cell Breast Augmentation Study